Skip to main content
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Am J Gastroenterol. 2015 Nov 3;110(12):1666–1674. doi: 10.1038/ajg.2015.358

Figure 3.

Figure 3

Cost-effectiveness acceptability curve plot of the competing strategies. Across the tested willingness to pay range, the majority of trials found ERCP with FDA-recommended reprocessing to be the most cost-effective approach.

CBDE = common bile duct exploration; ERCP = endoscopic retrograde cholangiopancreatography; EtO = ethylene oxide; FDA = Food and Drug Administration; LC = laparoscopic cholecystectomy.